Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

VERTEX PHARMACEUTICALS INC / MA

VRTX · Nasdaq · CIK 0000875320 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

28 Form 4 transaction lines observed in the same window
14 sales · 14 option, withholding, award, gift or other lines

Last qualifying purchase2025-08-06 · Kewalramani Reshma · $3.9M

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Bozic CarmenEVP and CMO
▼▼▼▼▼▼▼
Liu JoyEVP and Chief Legal Officer
▼▼▼
Bhatia Sangeeta N.Director
○▼
Thornberry NancyDirector
○○
Schneider JenniferDirector
○○
MCKENZIE DIANADirector
○○
● Purchase▼ Sale○ Other

Showing the six most active owners; 9 additional owner(s) remain in Form 4 evidence.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-08-06 · Kewalramani Reshma.

Recent Form 4 activity

0Purchases
93Sales
97Other Form 4 lines
97SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING14 sale line(s) · context only
OTHER14 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
4,503,200
Previous report
4,716,867
Avg daily volume
1,063,142
Days to cover
4.2

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2025-08-06SACHS BRUCE IPurchase (P)Common Stock5,000USD 389.68USD 1,948,416SEC filing ↗
2025-08-06Kewalramani ReshmaPurchase (P)Common Stock10,000USD 389.58USD 3,895,768SEC filing ↗
2021-08-19Kewalramani ReshmaPurchase (P)Common Stock10,000USD 195.65USD 1,956,492SEC filing ↗
2021-08-02SACHS BRUCE IPurchase (P)Common Stock15,000USD 197.91USD 2,968,650SEC filing ↗
2020-11-10SACHS BRUCE IPurchase (P)Common Stock15,000USD 217.36USD 3,260,465SEC filing ↗

Form 4 evidence

190 transaction lines in the latest 365-day window; 1,980 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-08van Grunsven JasperAward / grant (A)Common Stock8,682USD 0.00USD 0SEC filing ↗
2026-08-28Ambrose KristenAward / grant (A)Common Stock5,000USD 0.00USD 0SEC filing ↗
2026-08-27SACHS BRUCE IGift (G)Common Stock6,000USD 0.00USD 0SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-08van Grunsven JasperAward / grant (A)Common Stock8,682USD 0.00USD 0SEC filing ↗
2026-08-28Ambrose KristenAward / grant (A)Common Stock5,000USD 0.00USD 0SEC filing ↗
2026-08-27SACHS BRUCE IGift (G)Common Stock6,000USD 0.00USD 0SEC filing ↗
2026-07-21Tatsis OuraniaAward / grant (A)Common Stock8,251USD 0.00USD 0SEC filing ↗
2026-07-21Sachdev AmitAward / grant (A)Common Stock8,251USD 0.00USD 0SEC filing ↗
2026-07-02Tatsis OuraniaSale (S)Common Stock1,500USD 524.99USD 787,485SEC filing ↗
2026-07-02McKechnie DuncanSale (S)Common Stock1,541USD 519.00USD 799,779SEC filing ↗
2026-07-01Liu JoySale (S)Common Stock828USD 502.71USD 416,244SEC filing ↗
2026-06-26Bozic CarmenSale (S)Common Stock596USD 482.50USD 287,570SEC filing ↗
2026-06-18Bozic CarmenSale (S)Common Stock1,020USD 462.17USD 471,413SEC filing ↗
2026-06-15Bozic CarmenSale (S)Common Stock4,062USD 450.00USD 1,827,900SEC filing ↗
2026-06-05Bozic CarmenSale (S)Common Stock1,745USD 450.00USD 785,250SEC filing ↗
2026-06-01Liu JoySale (S)Common Stock828USD 439.91USD 364,245SEC filing ↗
2026-05-29Bozic CarmenSale (S)Common Stock1,974USD 450.00USD 888,300SEC filing ↗
2026-05-15Bunnage Mark E.Sale (S)Common Stock33USD 453.45USD 14,964SEC filing ↗
2026-05-15Bozic CarmenSale (S)Common Stock1,354USD 453.45USD 613,971SEC filing ↗
2026-05-12Bozic CarmenSale (S)Common Stock6,988USD 450.00USD 3,144,600SEC filing ↗
2026-05-04Bhatia Sangeeta N.Sale (S)Common Stock318USD 423.73USD 134,746SEC filing ↗
2026-05-01Upadhyay SuketuD (D)Common Stock796USD —USD —SEC filing ↗
2026-05-01Thornberry NancyD (D)Common Stock398USD —USD —SEC filing ↗
2026-05-01Thornberry NancyAward / grant (A)Common Stock472USD 0.00USD 0SEC filing ↗
2026-05-01Schneider JenniferD (D)Common Stock796USD —USD —SEC filing ↗
2026-05-01Schneider JenniferAward / grant (A)Common Stock472USD 0.00USD 0SEC filing ↗
2026-05-01MCKENZIE DIANAD (D)Common Stock796USD —USD —SEC filing ↗
2026-05-01MCKENZIE DIANAAward / grant (A)Common Stock943USD 0.00USD 0SEC filing ↗
2026-05-01Liu JoySale (S)Common Stock1,104USD 425.02USD 469,222SEC filing ↗
2026-05-01Garber Alan MAward / grant (A)Common Stock472USD 0.00USD 0SEC filing ↗
2026-05-01Bhatia Sangeeta N.Award / grant (A)Common Stock943USD 0.00USD 0SEC filing ↗
2026-04-01Liu JoySale (S)Common Stock978USD 449.17USD 439,288SEC filing ↗
2026-03-27Bozic CarmenSale (S)Common Stock2,329USD 450.95USD 1,050,263SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerVRTX
CIK0000875320
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history1,980 transaction lines from 2020-01-02 to 2026-09-08
10 P purchase lines · 1,268 S sale lines · 702 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.